Eicke Latz to Inflammation Mediators
This is a "connection" page, showing publications Eicke Latz has written about Inflammation Mediators.
Connection Strength
1.632
-
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013 Jun; 13(6):397-411.
Score: 0.396
-
Grebe A, Latz E. IL-1, quo vadis? Atherosclerosis. 2012 Jun; 222(2):324-5.
Score: 0.365
-
Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008 Aug; 9(8):847-56.
Score: 0.282
-
Latz E, Duewell P. NLRP3 inflammasome activation in inflammaging. Semin Immunol. 2018 12; 40:61-73.
Score: 0.143
-
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 Apr; 14(4):388-405.
Score: 0.112
-
Kim TW, Febbraio M, Robinet P, Dugar B, Greene D, Cerny A, Latz E, Gilmour R, Staschke K, Chisolm G, Fox PL, DiCorleto PE, Smith JD, Li X. The critical role of IL-1 receptor-associated kinase 4-mediated NF-?B activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis. J Immunol. 2011 Mar 01; 186(5):2871-80.
Score: 0.084
-
Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest. 2009 Dec; 119(12):3502-11.
Score: 0.078
-
Davanso MR, Crisma AR, Braga TT, Masi LN, do Amaral CL, Leal VNC, de Lima DS, Patente TA, Barbuto JA, Corr?a-Giannella ML, Lauterbach M, Kolbe CC, Latz E, Camara NOS, Pontillo A, Curi R. Macrophage inflammatory state in Type 1 diabetes: triggered by NLRP3/iNOS pathway and attenuated by docosahexaenoic acid. Clin Sci (Lond). 2021 01 15; 135(1):19-34.
Score: 0.042
-
Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger ?, Orrem HL, Sporsheim B, Ryan L, Kong XY, Dahl TB, Skjelland M, S?rensen KK, Rokstad AM, Yndestad A, Latz E, Gullestad L, Andersen G?, Dam?s JK, Aukrust P, Mollnes TE, Halvorsen B, Espevik T. Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. EBioMedicine. 2020 Oct; 60:102985.
Score: 0.041
-
Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM, Samuel CS, Kemp-Harper BK, Robertson AAB, Cooper MA, Peter K, Latz E, Mansell AS, Sobey CG, Drummond GR, Vinh A. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019 03 15; 115(4):776-787.
Score: 0.037
-
Bakke SS, Aune MH, Niyonzima N, Pilely K, Ryan L, Skjelland M, Garred P, Aukrust P, Halvorsen B, Latz E, Dam?s JK, Mollnes TE, Espevik T. Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation. J Immunol. 2017 10 15; 199(8):2910-2920.
Score: 0.033
-
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008 Aug; 9(8):857-65.
Score: 0.018